Aeglea Bio Therapeutics Performance
| AGLEDelisted Stock | USD 0.59 0.01 1.72% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Aeglea Bio are completely uncorrelated. Aeglea Bio Therapeutics right now shows a risk of 0.0%. Please confirm Aeglea Bio Therapeutics rate of daily change and period momentum indicator , to decide if Aeglea Bio Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Aeglea Bio Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound essential indicators, Aeglea Bio is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 17 M | |
| Free Cash Flow | -80.2 M |
Aeglea |
Aeglea Bio Relative Risk vs. Return Landscape
If you would invest 59.00 in Aeglea Bio Therapeutics on November 2, 2024 and sell it today you would earn a total of 0.00 from holding Aeglea Bio Therapeutics or generate 0.0% return on investment over 90 days. Aeglea Bio Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Aeglea, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aeglea Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aeglea Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aeglea Bio Therapeutics, and traders can use it to determine the average amount a Aeglea Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| AGLE |
Based on monthly moving average Aeglea Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aeglea Bio by adding Aeglea Bio to a well-diversified portfolio.
Aeglea Bio Fundamentals Growth
Aeglea Stock prices reflect investors' perceptions of the future prospects and financial health of Aeglea Bio, and Aeglea Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aeglea Stock performance.
| Return On Equity | -2.81 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | (94.85) % | |||
| Current Valuation | 228.21 M | |||
| Shares Outstanding | 4.05 M | |||
| Price To Earning | (2.41) X | |||
| Price To Book | 0.35 X | |||
| Price To Sales | 4.08 X | |||
| Revenue | 2.33 M | |||
| EBITDA | (84.78 M) | |||
| Cash And Equivalents | 73.68 M | |||
| Cash Per Share | 1.20 X | |||
| Total Debt | 4.63 M | |||
| Debt To Equity | 0.07 % | |||
| Book Value Per Share | (60.61) X | |||
| Cash Flow From Operations | (80.14 M) | |||
| Earnings Per Share | (74.15) X | |||
| Total Asset | 71.14 M | |||
| Retained Earnings | (425.62 M) | |||
| Current Asset | 38.29 M | |||
| Current Liabilities | 2.52 M | |||
About Aeglea Bio Performance
By analyzing Aeglea Bio's fundamental ratios, stakeholders can gain valuable insights into Aeglea Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Aeglea Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aeglea Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Aeglea Biothera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.Things to note about Aeglea Bio Therapeutics performance evaluation
Checking the ongoing alerts about Aeglea Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aeglea Bio Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aeglea Bio is not yet fully synchronised with the market data | |
| Aeglea Bio has some characteristics of a very speculative penny stock | |
| Aeglea Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.33 M. Net Loss for the year was (83.81 M) with loss before overhead, payroll, taxes, and interest of (262 K). | |
| Aeglea Bio Therapeutics currently holds about 73.68 M in cash with (80.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.2, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Aeglea Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aeglea Bio's stock is overvalued or undervalued compared to its peers.
- Examining Aeglea Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aeglea Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aeglea Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aeglea Bio's stock. These opinions can provide insight into Aeglea Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |